Retevmo

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia.

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.
This medicine is new or being used differently. Please report side effects. See the full CMI for further details.

1. Why am I taking RETEVMO?

RETEVMO contains the active ingredient selpercatinib. RETEVMO is used to treat a type of lung cancer (non-small cell lung cancer (NSCLC)) in adults, caused by an abnormal RET gene.
For more information, see Section 1. Why am I taking RETEVMO? in the full CMI.

2. What should I know before I take RETEVMO?

Do not take if you have ever had an allergic reaction to RETEVMO or any of the ingredients listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.
For more information, see Section 2. What should I know before I take RETEVMO? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with RETEVMO and affect how it works.
A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How do I take RETEVMO?

Your doctor will prescribe the right dose for you. The maximum doses are:
for patients with less than 50 kg body weight: 120 mg twice a day
for patients with 50 kg body weight or greater: 160 mg twice a day
More instructions can be found in Section 4. How do I take RETEVMO? in the full CMI.

5. What should I know while taking RETEVMO?

Things you should do
You and your partner should use an effective method of birth control (contraception) to avoid becoming pregnant while taking RETEVMO and for at least one week after your final dose.
Tell your doctor straight away if you experience any signs of bleeding or liver problems.
You will need to have regular blood tests, blood pressure checks and ECG testing.
Remind any doctor, dentist or pharmacist you visit that you are using RETEVMO.
Things you should not do
Do not take RETEVMO to treat any other complaints unless your doctor tells you to.
Do not give your medicine to anyone else, even if they have the same condition as you.
Do not stop taking your medicine, or change the dosage, without checking with your doctor.
Driving or using machines
Be careful before you drive or use any machines or tools until you know how RETEVMO affects you.
RETEVMO may make you feel tired or dizzy.
Looking after your medicine
Keep your capsules in the original pack until it is time to take them.
This medicine does not require any special storage conditions.
For more information, see Section 5. What should I know while taking RETEVMO? in the full CMI.

6. Are there any side effects?

Potential side effects include swelling, diarrhoea, tiredness, dry mouth, abdominal pain, constipation, rash, nausea, headache, vomiting, dizziness, decreased appetite, fever. Serious potential side effects include severe or life threatening inflammation of the lungs, raised liver enzymes, high blood pressure, bleeding, heart rhythm changes (which prolong the QT interval), low thyroid hormone levels (characterised by weight gain, feeling cold, tiredness that worsens or does not go away, constipation) and allergic reactions (characterised by fever, rash, and muscle and joint pain).
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
You can help by reporting any side effects you may get. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems .
Active ingredient: selpercatinib
This medicine has provisional approval for the treatment of adults with a type of lung cancer called non-small cell lung cancer (NSCLC). The decision to approve this medicine has been made on the basis of promising results from a preliminary study. More evidence is required to be submitted when available to fully confirm the benefit and safety of the medicine for this use.

Full Consumer Medicine Information (CMI)

This leaflet provides important information about using RETEVMO. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about taking RETEVMO.
Where to find information in this leaflet:

1. Why am I taking RETEVMO?

RETEVMO contains the active ingredient selpercatinib. RETEVMO is an anti-cancer prescription medicine.
RETEVMO is used to treat a lung cancer, called non-small cell lung cancer (NSCLC), in adults, caused by abnormal changes in the RET gene.
Your doctor will perform a test to check if your cancer has a change in the RET gene to make sure that RETEVMO is right for you.
In patients whose cancer has an altered RET gene, the change in the gene causes the body to make an abnormal RET protein, which can lead to uncontrolled cell growth and cancer. RETEVMO blocks the action of the abnormal RET protein and so may slow or stop the growth of the cancer. It may also help to shrink the cancer.

2. What should I know before I take RETEVMO?

Warnings

Do not take RETEVMO if:

you are allergic to selpercatinib, or any of the ingredients listed at the end of this leaflet.
Always check the ingredients to make sure you can use this medicine.

Check with your doctor if you:

have liver problems.
have lung or breathing problems other than lung cancer.
have high blood pressure.
have heart problems including a condition called QT prolongation.
have bleeding problems.
have a history of kidney problems or low blood pressure as this may increase your risks associated with tumour lysis syndrome (TLS).
take any medicines for any other condition, including prescription, over the counter medicines, vitamins, minerals and herbal supplements.
During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Tell your doctor if you or your partner are pregnant or intend to become pregnant.
RETEVMO can harm your unborn baby.
Females who are able to become pregnant should use an effective method of birth control (contraception) to avoid becoming pregnant while taking RETEVMO and for at least one week after your final dose. Your doctor can discuss the risks and benefits involved.
Males with female partners, who are able to become pregnant, should use effective method of contraception during treatment with RETEVMO and for at least 1 week after the final dose of RETEVMO.
Talk to your doctor if you are breastfeeding or intend to breastfeed.
It is not known if RETEVMO passes into your breastmilk.
Do not breastfeed if you are taking RETEVMO and for at least 1 week after the last dose.

Use in children

RETEVMO is not intended for use by children under the age of 18 years.

Use in elderly

RETEVMO may be used in elderly patients aged 65 years and over.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.
Some medicines may interfere with RETEVMO and affect how it works.
Medicines that may increase the effect of RETEVMO include:
itraconazole, ketoconazole, posaconazole, voriconazole (used to treat fungal infections)
ritonavir, saquinavir (used to treat HIV infections/AIDS)
Medicines that may reduce the effect of RETEVMO include:
carbamazepine (used to treat epilepsy, nerve pain, bipolar disorder)
phenytoin, phenobarbital (used to treat epilepsy)
rifampicin, rifabutin (used to treat tuberculosis (TB) and some other infections)
St. John’s wort (a herbal product used to treat mild depression and anxiety)
RETEVMO may affect the way some medicines work, including the following:
medicines that are a substrate of the liver enzyme CYP3A4, for example:
midazolam (used for sedation prior surgery)
alfentanil (used in anaesthetic procedures)
avanafil, vardenafil (used to treat erectile dysfunction)
darunavir (used to treat HIV infections)
naloxegol (used to treat constipation)
simvastatin (used to treat high blood cholesterol)
medicines that are a substrate of the liver enzyme CYP2C8, for example:
enzalutamide, paclitaxel, sorafenib (used to treat different cancers)
buprenorphine (used to treat pain or, when combined with another medicine, opiate dependance)
selexipag (used to treat hypertension)
montelukast (used to treat asthma)
ranitidine or other H2 blockers (used to treat ulcers and acid reflux).
omeprazole or other proton pump inhibitors (used to treat heartburn, ulcers, and acid reflux).
dabigatran (used to treat deep vein thrombosis and clots in lung, and used to prevent stroke)
digoxin (used to treat heart disorders).
Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect RETEVMO.

4. How do I take RETEVMO?

How much to take

Your doctor will prescribe the right dose for you.
The maximum recommended dose is:
for patients with less than 50 kg body weight: 120 mg twice a day
for patients with 50 kg body weight or greater: 160 mg twice a day.
Follow the instructions provided and use RETEVMO until your doctor tells you to stop.
If you get certain side effects while you are taking RETEVMO your doctor may lower your dose or stop treatment temporarily or permanently.

When to take RETEVMO

RETEVMO is taken twice a day at about the same time every day, preferably in the morning and evening.
Swallow the capsule whole with a glass of water. Do not chew, crush or split the capsule before swallowing.
You can take the capsules either with or without food. Please note, if you are also taking omeprazole or other proton pump inhibitors (used to treat heartburn, ulcers, and acid reflux), then take RETEVMO with a full meal.
If you are also taking ranitidine or other H2 blockers (used to treat ulcers and acid reflux), then take RETEVMO 2 hours before or 10 hours after taking them.
If you are taking omeprazole or other proton pump inhibitors (used to treat heartburn, ulcers, and acid reflux), then take RETEVMO with a full meal.
If you are taking antacid containing aluminium, magnesium, calcium, simethicone, or buffered medicines, then take RETEVMO 2 hours before or 2 hours after.

If you forget to take RETEVMO

If you vomit after taking the dose or forget a dose, take your next dose at your usual time. Do not take a double dose to make up for the forgotten or vomited dose.

If you take too much RETEVMO

If you think that you have taken too much RETEVMO, you may need urgent medical attention.
You should immediately:
phone the Poisons Information Centre
(by calling 13 11 26), or
contact your doctor, or
go to the Emergency Department at your nearest hospital.
You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while taking RETEVMO?

Things you should do

RETEVMO may cause inflammation of the lungs. Your doctor will monitor you before and during treatment with Retevmo for symptoms. Tell your doctor right away if you notice any symptoms of lung problems including breathlessness, cough and raised temperature as your dose may need to be lowered, or treatment paused.
You will have regular blood tests before and during treatment with RETEVMO, to check your liver function and electrolytes (such as sodium, potassium, magnesium and calcium) in your blood.
RETEVMO may result in abnormal ECGs. You will have an ECG taken before and during your treatment with RETEVMO. Tell your doctor if you experience fainting as it may be a symptom of abnormal ECG.
RETEVMO may affect your blood pressure. Your blood pressure will be measured before and during your treatment.
RETEVMO can affect the way your wounds heal. Tell your doctor if you plan to have surgery. You may need to stop taking RETEVMO at least 7 days before your planned surgery and at least 2 weeks after the surgery.
Your doctor will do blood tests to check your thyroid function before and during treatment with RETEVMO. Tell your doctor if you develop signs or symptoms of low thyroid hormone levels such as weight gain, feeling cold, tiredness that worsens or that does not go away and constipation. Your doctor may prescribe you thyroid hormone replacement and/or your treatment with RETEVMO may be paused until your thyroid hormone levels normalise.
Your doctor may do blood tests to check you for tumour lysis syndrome (TLS). TLS is caused by a fast breakdown of cancer cells. It can cause kidney failure, the need for dialysis treatment, and an abnormal heartbeat. Staying well hydrated may help prevent TLS from occurring.
Call your doctor or go to emergency if you develop nausea, vomiting, weakness, swelling, shortness of breath, muscle cramps and seizures during treatment of RETEVMO.

Call your doctor straight away if you:

experience signs of bleeding (see additional information under Section 6. Are there any side effects? )
develop symptoms of liver problems (see additional information under Section 6. Are there any side effects? )
become pregnant while taking this medicine.
You and your partner should use an effective method of contraception to avoid becoming pregnant while taking RETEVMO and for at least one week after your final dose.
Remind any doctor, dentist or pharmacist you visit that you are using RETEVMO.

Things you should not do

Do not take RETEVMO to treat any other complaints unless your doctor tells you to.
Do not give your medicine to anyone else, even if they have the same condition as you.
Do not stop taking your medicine, or change the dosage, without checking with your doctor.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how RETEVMO affects you.
RETEVMO may make you feel tired or dizzy.

Looking after your medicine

Keep your capsules in the original pack until it is time to take them.
Store below 30°C.
Keep it where young children cannot reach it.

When to discard your medicine

Do not take this medicine if the inner seal is broken or the packaging is torn or shows signs of tampering.
If it is damaged, return it to your pharmacist for safe disposal.

Getting rid of any unwanted medicine

If you no longer need to use medicine or it is out of date, take it to any pharmacy for safe disposal.
Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.
See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effects
What to do
Gastrointestinal related:
abdominal pain
diarrhoea
nausea
vomiting
constipation
dry mouth
Metabolism related:
decreased appetite
Nervous system related:
headache
dizziness
Skin disorder:
rash
General disorders:
fever
tiredness
swelling
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effects
What to do
Liver related:
Increase in liver enzymes (ALT or AST)
Symptoms may include:
yellowing of your skin or the white part of your eyes (jaundice)
loss of appetite
nausea or vomiting
dark urine
pain on the upper right side of your stomach area
sleepiness
bleeding or bruising
Thyroid related:
Low thyroid levels
Symptoms may include:
weight gain
feeling cold
tiredness that worsens or that does not go away
constipation
Blood pressure related:
high blood pressure
Symptoms may include:
confusion
dizziness
headaches
chest pain
shortness of breath
Heart related:
heart rhythm changes (which prolong the QT interval)
Symptoms may include:
loss of consciousness
fainting
dizziness
a change in the way your heart beats (heart palpitations)
Allergy related:
allergic reactions, characterised by fever, rash, and muscle and joint pain, typically in the first month of treatment.
Tell your doctor if you have any of these serious side effects as you may require medical attention.
Blood related:
bleeding
Signs may include:
vomiting blood or if your vomit looks like coffee-grounds
coughing up blood or blood clots
unusual vaginal bleeding or menstrual bleeding that is heavier than normal
nose bleeds that happen often
pink or brown urine
red or black (looks like tar) stools
unusual bleeding or bruising of your skin
Lung related:
inflammation of the lungs
Symptoms may include:
breathlessness
cough
fever
Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Elderly patients aged 65 years and older may experience a higher number of side effects.
Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.
Some side effects (for example, changes in liver or other enzymes, kidney markers, electrolyte levels and blood cells levels) can only be found when your doctor does tests from time to time.
Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects that you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems . By reporting side effects, you can help provide more information on the safety of this medicine.
Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What RETEVMO contains

Active ingredient
(main ingredient)
selpercatinib
Other ingredients
(inactive ingredients)
Capsule content:
microcrystalline cellulose
colloidal anhydrous silica
40 mg capsule shell:
gelatin
titanium dioxide
iron oxide black
80 mg capsule shell:
gelatin
titanium dioxide
Brilliant Blue FCF
Capsule shell black ink:
TekPrint SW-9049 Black Ink
Do not take this medicine if you are allergic to any of these ingredients.

What RETEVMO looks like

RETEVMO 40 mg is a grey, opaque capsule imprinted with "Lilly 3977" and "40 mg" in black ink (Aust R 391331).
RETEVMO 80 mg is a blue, opaque capsule imprinted with "Lilly 2980" and "80 mg" in black ink (Aust R 391330).

Who distributes RETEVMO

Eli Lilly Australia Pty Ltd
Level 9, 60 Margaret Street, Sydney, NSW 2000
AUSTRALIA
®= Registered Trademark
If you have any questions about RETEVMO, contact Eli Lilly at 1800 454 559 (Australia) or your healthcare professional for assistance.
This leaflet was prepared in July 2023.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.